## ON-LINE APPENDIX

## Inclusion and Exclusion Criteria for the Pretreatment and Palliative Groups

Inclusion criteria for the pretreatment group were staging of disease according to the American Joint Committee on Cancer criteria, no evidence of distant metastasis, white blood cell count, $>3500$; platelet count, $>10,000$; creatinine clearance, $>60$; bilirubin level, $<1.5$; age older than 18 years. Patients with prior head and neck malignancy, history of head or neck irradiation, prior chemotherapy, medical contraindication to chemotherapy, surgery, or radiation therapy, and/or a positive pregnancy test were excluded from the pretreatment group.

Inclusion criteria for the palliative group included histologically or cytologically confirmed diagnosis of stage IVc (meta-
static) or locally recurrent advanced head and neck squamous cell carcinoma not amenable to surgery or palliative radiotherapy; no more than 2 prior systemic chemotherapeutic regimens for head and neck squamous cell carcinoma in the locally advanced or metastatic setting and having relapsed after or have been refractory to therapy; serum creatinine level, $\leq 2.0$ times the upper limit of normal; serum albumin level, $\geq 3.0 \mathrm{~g} / \mathrm{dL}$; total bilirubin level, $\leq 1.0$ times the upper limit of normal; and serum aspartate aminotransferase and serum alanine aminotransferase levels $\leq 2.5$ times the upper limit of normal for the testing laboratory. Exclusion criteria for the palliative group included pregnant or nursing women, prior docetaxel treatment for head and neck squamous cell carcinoma in the metastatic setting, any concurrent therapy intended to treat head and neck squamous cell carcinoma, and active secondary malignancy or history of other malignancy within the past 5 years.

On-line Table 1: Summary of patient demographics and laboratory testing results

| Patient No. | p16 | EGFR | HPV | Age (yr) | Sex | Tumor Site | Stage |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Pretreatment |  |  |  |  |  |  |  |
| 1 | Negative | Positive | Negative | 53 | F | Tongue base | T4n2c |
| 2 | Positive | Negative | Positive | 46 | M | Left tonsil | T3N2b |
| 3 | Positive | Positive | Positive | 63 | M | Tongue base | T1N2c |
| 4 | - | - | Negative | 46 | F | Left false vocal cord | T3N2b |
| 5 | Negative | Positive | Negative | 72 | F | Left tongue base | T4N2c |
| 6 |  | - | Negative | 67 | M | False vocal fold | T4N2b |
| 7 | - | - | Negative | 63 | M | Epiglottis | T3N3 |
| 8 | Positive | Positive | Positive | 53 | M | Right tongue base | T2N1 |
| 9 | Negative | Negative | Negative | 55 | M | Right tonsil | T4N2b |
| 10 | Negative | Positive | Negative | 80 | F | Right lateral tongue | T3N0 |
| 11 | Positive | Positive | Positive | 55 | M | Left tongue base | T2N2a |
| 12 | Negative | Negative | Negative | 50 | F | Epiglottis | T3N0 |
| 13 | Negative | Positive | Negative | 57 | F | Left tonsil | T2N2a |
| 14 | - | - | Negative | 78 | F | Vallecula | T3N1 |
| 15 | Negative | Positive | Negative | 40 | M | Left buccal mucosa | T3N0 |
| 16 | Negative | Positive | Negative | 66 | M | Glottis | T3N0 |
| 17 | Negative | Negative | Negative | 54 | M | Nasopharynx | T4bN2b |
| 18 | Negative | Positive | Negative | 67 | M | Left retromolar trigone | T4N1 |
| Palliative |  |  |  |  |  |  |  |
| 19 | Negative | Positive | Negative | 57 | M | Left lateral tongue recurrence |  |
| 20 | Negative | - | Negative | 62 | M | Right neck nodal disease |  |
| 21 | Negative | Negative | Negative | 73 | F | Peristomal recurrence |  |
| 22 | Negative | Positive | Negative | 68 | M | Right parotid gland |  |
| 23 | Negative | Positive | Negative | 54 | M | Peristomal recurrence |  |
| 24 | Positive | Positive | Positive | 46 | M | Right masticator space metastasis |  |
| 25 | Negative | Positive | Negative | 41 | M | Left floor of mouth recurrence |  |

Note:-- indicates not tested due to insufficient sample or tissue quantity.

On-line Table 2: CTP values of patients

| Patient No. | $\begin{gathered} \mathrm{BF} \\ (\mathrm{~mL} / 100 \mathrm{~g} / \mathrm{min}) \end{gathered}$ | $B F \pm S D$ | $\begin{gathered} \hline \text { BV } \\ (\mathrm{mL} / 100 \mathrm{~g}) \end{gathered}$ | $B V \pm S D$ | $\begin{aligned} & \text { MTT } \\ & (\mathrm{sec}) \end{aligned}$ | MTT $\pm$ SD | $\begin{gathered} \mathrm{CP} \\ (\mathrm{~mL} / 100 \mathrm{~g} / \mathrm{min}) \end{gathered}$ | $\mathrm{CP} \pm \mathrm{SD}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Pretreatment |  |  |  |  |  |  |  |  |
| 1 | 75.59 | 52.06 | 4.28 | 2.21 | 4.76 | 3.55 | 15.35 | 6.77 |
| 2 | 108.17 | 130 | 7.31 | 4.15 | 12.58 | 13.16 | 27.16 | 18.91 |
| 3 | 183.65 | 140.87 | 12.07 | 8.83 | 7.4 | 8.71 | 29.96 | 24.03 |
| 4 | 112.67 | 84.67 | 5.49 | 3.53 | 6.58 | 8.42 | 16.03 | 13.66 |
| 5 | 54.52 | 30.93 | 2.95 | 1.01 | 4.4 | 2.73 | 12.87 | 3.03 |
| 6 | 90 | 80.48 | 9.61 | 5.25 | 10.34 | 7.98 | 25.77 | 25.71 |
| 7 | 113.71 | 98.97 | 10.35 | 5.74 | 9.14 | 8.19 | 19.77 | 19.02 |
| 8 | 77.93 | 45.69 | 5.08 | 1.97 | 5.11 | 3.27 | 13.4 | 6.76 |
| 9 | 76.1 | 68.85 | 5.14 | 2.8 | 7.04 | 6.31 | 19.05 | 8.89 |
| 10 | 78.13 | 41.79 | 9.11 | 3.81 | 8.62 | 4.27 | 13.1 | 12.23 |
| 11 | 168.24 | 102.52 | 8.21 | 4.25 | 4 | 3.25 | 23.58 | 20.3 |
| 12 | 190.15 | 69.06 | 9.1 | 4.1 | 3.83 | 3.73 | 18.18 | 13.17 |
| 13 | 190.78 | 101.98 | 6.59 | 3.81 | 2.42 | 1.53 | 17.23 | 10.76 |
| 14 | 112.57 | 133.74 | 10.62 | 6.31 | 11.47 | 9.5 | 28 | 20.12 |
| 15 | 108.54 | 135.29 | 5.37 | 4.18 | 5.48 | 5.54 | 10.42 | 8.94 |
| 16 | 361.04 | 294.82 | 24.15 | 15.94 | 6.47 | 6.1 | 9.76 | 25.04 |
| 17 | 60.684 | 25.9 | 6.593 | 2.45 | 8.142 | 4.48 | 42.282 | 26.99 |
| 18 | 72.539 | 38.154 | 9.5332 | 5.13 | 9.2703 | 3.83 | 16.729 | 3.83 |
| Palliative |  |  |  |  |  |  |  |  |
| 19 | 84.757 | 55.17 | 8.408 | 6.89 | 6.137 | 2.35 | 32.724 | 24.32 |
| 20 | 4.917 | 3.22 | 0.694 | 0.42 | 9.38 | 3.74 | 1.13 | 1.84 |
| 21 | 91.69 | 41.84 | 8.69 | 3.93 | 7.35 | 4.29 | 79.84 | 19.2 |
| 22 | 61.08 | 12.68 | 8.01 | 1.86 | 8.57 | 2.26 | 63.1 | 17.99 |
| 23 | 14.78 | 3.55 | 103.71 | 28.75 | 9.71 | 3.91 | 61.21 | 22.9 |
| 24 | 69.22 | 26.16 | 8.55 | 4.57 | 8.1 | 4.54 | 58 | 24.57 |
| 25 | 29.86 | 17.85 | 5.08 | 2.97 | 13.81 | 9.29 | 29.43 | 20.74 |

